{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:16:28Z","timestamp":1783937788293,"version":"3.55.0"},"reference-count":39,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0707","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T22:06:06Z","timestamp":1615413966000},"page":"791-805","source":"Crossref","is-referenced-by-count":16,"title":["Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan"],"prefix":"10.1507","volume":"68","author":[{"given":"Akira","family":"Shimatsu","sequence":"first","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"},{"name":"Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan"},{"name":"Department of Diabetes and Endocrinology, Nara Medical University, Kashihara 634-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital, Sendai 980-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Nippon Medical School, Tokyo 113-8603, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo 105-8470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes & Metabolism, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"},{"name":"International Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Teijin Pharma Limited, Tokyo 100-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Teijin Pharma Limited, Tokyo 100-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 \u00d3nnestam L, Berinder K, Burman P, Dahlqvist P, Engstr\u00f6m BE, et al. (2013) National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98: 626\u2013635.","DOI":"10.1210\/jc.2012-3362"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610\u2013638.","DOI":"10.1210\/edrv-17-6-610"},{"key":"3","unstructured":"3 (2018) Research group of \u201cHypothalamic-pituitary dysfunction,\u201d Research on rare and intractable disease, Health and Labour Sciences Grants from the Ministry of Health, Labour and Welfare, The Japan Endocrine Society (ed) Guidelines for diagnosis and treatment of Hypothalamic-pituitary dysfunction (revised in 2018) (9) Guidelines or diagnosis and treatment of pituitary TSH-secreting tumor. https:\/\/www.jstage.jst.go.jp\/article\/endocrine\/95\/S.May\/95_1\/_pdf\/-char\/ja accessed on January 19, 2021 (In Japanese)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL (2013) 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2: 76\u201382.","DOI":"10.1159\/000351007"},{"key":"5","unstructured":"5 Japan Thyroid Association and the Japan Endocrine Society (ed) (2017) Guidelines for management of thyroid storm. Nankodo, Tokyo, Japan (In Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fujio S, Ashari, Habu M, Yamahata H, Moinuddin FM, et al. (2014) Thyroid storm induced by TSH-secreting pituitary adenoma: a case report. Endocr J 61: 1131\u20131136.","DOI":"10.1507\/endocrj.EJ14-0278"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Page KA, Roehmholdt BF, Jablonski M, Mayerson AB (2008) Development of thyroid storm after surgical resection of a thyrotropin-secreting pituitary adenoma. Endocr Pract 14: 732\u2013737.","DOI":"10.4158\/EP.14.6.732"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, et al. (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85: 1487\u20131491.","DOI":"10.1210\/jcem.85.4.6548"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, et al. (1994) Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 40: 421\u2013428.","DOI":"10.1111\/j.1365-2265.1994.tb03941.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, et al. (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 86: 2849\u20132853.","DOI":"10.1210\/jcem.86.6.7593"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K (1999) Treatment of thyrotropin-secreting pituitary adenomas with octreotide. Endocr J 46: 113\u2013123.","DOI":"10.1507\/endocrj.46.113"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, et al. (2014) Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 121: 1462\u20131473.","DOI":"10.3171\/2014.7.JNS1471"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, et al. (2015) Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J 62: 21\u201327.","DOI":"10.1507\/endocrj.EJ14-0118"},{"key":"14","unstructured":"14 Fujio S, Yoshimoto K (2018) TSH-secreting pituitary adenoma. No Shinkei Geka 46: 1053\u20131063 (In Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C (2020) Somatostatin analogs in clinical practice: a review. Int J Mol Sci 21: 1682.","DOI":"10.3390\/ijms21051682"},{"key":"16","unstructured":"16 Osamura RY, Grossman A, Nishioka H, Trouillas J (2017) Pituitary gland: Thyrotroph adenoma. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosa\u00ef J (eds) WHO Classification of Tumours of Endocrine Organs (4th). International Agency for Research on Cancer, Lyon, France: 28\u201329."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, et al. (2007) Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J 54: 371\u2013378.","DOI":"10.1507\/endocrj.K06-177"},{"key":"18","unstructured":"18 Somatuline LA [package insert]. Berkshire, UK: Ipsen Limited; 2019. https:\/\/www.medicines.org.uk\/emc\/product\/965\/smpc#gref accessed on January 19, 2021."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, et al. (2013) Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J 60: 651\u2013663.","DOI":"10.1507\/endocrj.EJ12-0417"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, et al. (2016) Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer 47: 366\u2013374.","DOI":"10.1007\/s12029-016-9866-9"},{"key":"21","unstructured":"21 Somatuline AutoSolution [package insert]. Hoofddorp, The Netherlands: IPSEN FARMACEUTICA B.V; 2019. https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h26301_smpc.pdf accessed on January 19, 2021 (In Dutch)."},{"key":"22","unstructured":"22 Somatuline [package insert]. Tokyo, Japan: Teijin Pharma Limited; 2020. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/470310_2499413G1025_1_07 accessed on January 19, 2021 (In Japanese)."},{"key":"23","unstructured":"23 (2010) Research group of \u201cHypothalamic-pituitary dysfunction,\u201d Research program of intractable disease, Health and Labour Sciences Grants from the Ministry of Health, Labour and Welfare ed. Guidelines for diagnosis of TSH-secreting pituitary tumor (revised in 2010). http:\/\/square.umin.ac.jp\/kasuitai\/doctor\/guidance\/TSH_kasuitai.pdf accessed on January 19, 2021 (In Japanese)."},{"key":"24","unstructured":"24 (2019) MedDRA. Introductory Guide MedDRA Version 22.0. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_22_0_english.pdf accessed on January 19, 2021."},{"key":"25","unstructured":"25 (2015) Outline of hygiene administration report, the Ministry of Health, Labour and Welfare (at the end of 2015): Number of recipient certificates issued for specific disease treatment (for designated intractable disease) according to age group and disease group. https:\/\/www.nanbyou.or.jp\/wp-content\/uploads\/upload_files\/kouhu20161.pdf accessed on January 19, 2021 (In Japanese)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Sid\u00e9ris L, Dub\u00e9 P, Rinke A (2012) Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 17: 747\u2013755.","DOI":"10.1634\/theoncologist.2011-0458"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Paniagua AE, Bernabeu I, Leskela S, Marazuela M (2011) Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas. Clin Endocrinol (Oxf) 74: 406\u2013408.","DOI":"10.1111\/j.1365-2265.2010.03929.x"},{"key":"28","unstructured":"28 Tokutsu A, Okada Y, Torimoto K, Otsuka T, Narisawa M, et al. (2020) Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases. Neuro Endocrinol Lett 41: 10\u201316."},{"key":"29","doi-asserted-by":"publisher","unstructured":"29 Warszawski L, Kasuki L, S\u00e1 R, Dos Santos Silva CM, Volschan I, et al. (2016) Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19: 582\u2013589.","DOI":"10.1007\/s11102-016-0749-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, et al. (2002) Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 25: 971\u2013976.","DOI":"10.1007\/BF03344070"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Burke PG, Li Q, Costin ML, McMullan S, Pilowsky PM, et al. (2008) Somatostatin 2A receptor-expressing presympathetic neurons in the rostral ventrolateral medulla maintain blood pressure. Hypertension 52: 1127\u20131133.","DOI":"10.1161\/HYPERTENSIONAHA.108.118224"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Comunello A, Dassie F, Martini C, De Carlo E, Mioni R, et al. (2015) Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. Pituitary 18: 525\u2013534.","DOI":"10.1007\/s11102-014-0605-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, et al. (1993) Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab 76: 950\u2013955.","DOI":"10.1210\/jc.76.4.950"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Lakatos P, Foldes J, Nagy Z, Takacs I, Speer G, et al. (2000) Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. Thyroid 10: 417\u2013423.","DOI":"10.1089\/thy.2000.10.417"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Bronstein M, Musolino N, Jallad R, Cendros JM, Ramis J, et al. (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63: 514\u2013519.","DOI":"10.1111\/j.1365-2265.2005.02372.x"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36 Sriphrapradang C, Srichomkwun P, Refetoff S, Mamanasiri S (2016) A novel thyroid hormone receptor beta gene mutation (G251V) in a Thai patient with resistance to thyroid hormone coexisting with pituitary incidentaloma. Thyroid 26: 1804\u20131806.","DOI":"10.1089\/thy.2016.0450"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Teng X, Jin T, Brent GA, Wu A, Teng W, et al. (2015) A patient with a thyrotropin-secreting microadenoma and resistance to thyroid hormone (P453T). J Clin Endocrinol Metab 100: 2511\u20132514.","DOI":"10.1210\/jc.2014-3994"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, et al. (2005) Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf) 62: 176\u2013181.","DOI":"10.1111\/j.1365-2265.2004.02192.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Campi I, Covelli D, Moran C, Fugazzola L, Cacciatore C, et al. (2020) The differential diagnosis of discrepant thyroid function tests: insistent pitfalls and updated flow-chart based on a long-standing experience. Front Endocrinol (Lausanne) 11: 432.","DOI":"10.3389\/fendo.2020.00432"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/7\/68_EJ20-0707\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:31:56Z","timestamp":1715142716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/7\/68_EJ20-0707\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0707","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"EJ20-0707"}}